logo

Tcr2 Therapeutics (TCRR)



Trade TCRR now with
  Date
  Headline
9/17/2021 7:41:56 AM TCR² Therapeutics Reports Positive Interim Results From Phase 1/2 Trial Of Gavo-cel
9/2/2021 9:34:33 AM TCR² Therapeutics Receives FDA Orphan Drug Designation For Gavo-cel For Cholangiocarcinoma
1/19/2021 10:27:17 PM TCR2 Therapeutics Prices Underwritten Public Offering Of 4.59 Mln Shares At $30.50/shr
12/13/2020 9:48:43 AM TCR2 Therapeutics Reports Positive Interim Data From Phase 1 Portion Of TC-210 For Mesothelin-expressing Solid Tumors
7/28/2020 8:41:35 PM TCR2 Therapeutics Prices Public Offering Of 8 Mln Shares At $15.50/shr
3/30/2020 6:49:50 AM TCR² Therapeutics Q4 Loss Per Share $0.54 Vs Loss $16.22 Last Year
8/9/2019 7:48:00 AM Wedbush Is Raising TCR2 Therapeutics (TCRR) FY20 Estimate To -2.99 From -3.06
8/9/2019 7:47:48 AM Wedbush Is Lowering TCR2 Therapeutics (TCRR) Q4 20 Estimate To -0.74 From -0.73
8/9/2019 7:47:36 AM Wedbush Is Increasing TCR2 Therapeutics (TCRR) Q3 20 Estimate To -0.73 From -0.81
8/9/2019 7:47:22 AM Wedbush Is Lowering TCR2 Therapeutics (TCRR) Q2 20 Estimate To -0.81 From -0.78
8/9/2019 7:47:11 AM Wedbush Is Raising TCR2 Therapeutics (TCRR) Q1 20 Estimate To -0.71 From -0.74
8/9/2019 7:47:00 AM Wedbush Is Increasing TCR2 Therapeutics (TCRR) FY19 Estimate To -6.50 From -6.63
8/9/2019 7:46:48 AM Wedbush Is Increasing TCR2 Therapeutics (TCRR) Q4 19 Estimate To -0.63 From -0.71